Literature DB >> 12080621

[Hereditary hemorrhagic telangiectasia (Osler's disease). An interdisciplinary challenge].

U W Geisthoff1, G Schneider, J Fischinger, P K Plinkert.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT or Rendu-Osler-Weber disease) is an autosomal dominant inherited disease of the fibrovascular tissue. More than 90% of patients have recurrent nosebleeds. Therefore, ENT physicians often have a key position for diagnosis and management of the disease. Epistaxis can severely reduce the quality of life, but visceral lesions are also life threatening.
METHODS: This paper provides a review of the literature about the disease, its diagnosis, preventive measures, and therapy of the different manifestations. RESULTS AND
CONCLUSIONS: Physicians should be especially aware of gastrointestinal telangiectases, arteriovenous malformations (AVM) of the lungs, liver, and brain. A screening is recommended at least for pulmonary AVM.

Entities:  

Mesh:

Year:  2002        PMID: 12080621     DOI: 10.1007/s001060100537

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  8 in total

1.  Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Authors:  Kornelia E C Wirsching; Frank Haubner; Thomas S Kühnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-01-09       Impact factor: 2.503

2.  [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

Authors:  C Rohrmeier; T S Kühnel
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

3.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

4.  [Hereditary hemorrhagic telangiectasia. A rare treatable cause of stroke].

Authors:  D Ecker; U W Geisthoff; M Juchems; G Schneider; A C Ludolph; J Kassubek; R Huber
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

5.  Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations.

Authors:  Ajay Chavan; Martin Caselitz; Karl-Friedrich Gratz; Joachim Lotz; Timm Kirchhoff; Plinio Piso; Siegfried Wagner; Michael Manns; Michael Galanski
Journal:  Eur Radiol       Date:  2004-08-17       Impact factor: 5.315

6.  SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population.

Authors:  Sol Marcos; Virginia Albiñana; Lucia Recio-Poveda; Belisa Tarazona; María Patrocinio Verde-González; Luisa Ojeda-Fernández; Luisa-María Botella
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

7.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

8.  Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View.

Authors:  Kornelia E C Wirsching; Thomas S Kühnel
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.